TINAVI(688277)2024-10-29 10:38Financial Performance - The company's operating revenue for Q3 2024 was ¥33,807,308, a decrease of 34.67% compared to the same period last year[2]. - The net profit attributable to shareholders was -¥29,687,572, with a year-to-date net profit of -¥76,172,853, reflecting a significant loss[2]. - The basic and diluted earnings per share were both -¥0.07, compared to -¥0.17 in the same period last year[3]. - Total operating revenue for the first three quarters of 2024 was CNY 92,120,994.70, a decrease of 30.9% compared to CNY 133,666,408.30 in the same period of 2023[15]. - Net loss for the third quarter of 2024 was CNY 76,172,852.88, slightly improved from a net loss of CNY 76,992,237.38 in the same quarter of 2023[16]. - The company reported a gross profit margin of approximately -150.1% for the first three quarters of 2024, compared to -93.5% in the same period of 2023[15]. Research and Development - Research and development expenses totaled ¥31,686,854, accounting for 93.73% of operating revenue, an increase of 29.53 percentage points year-on-year[3]. - Research and development expenses for the first three quarters of 2024 amounted to CNY 70,657,967.30, a decrease of 18.4% from CNY 86,558,662.46 in the previous year[15]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,501,777,268, a decrease of 7.27% from the end of the previous year[3]. - As of September 30, 2023, the company's total assets amounted to approximately CNY 1.50 billion, a decrease from CNY 1.62 billion at the end of 2022[12]. - The company's total liabilities decreased to CNY 322,316,557.30 in Q3 2024 from CNY 381,951,829.60 in Q3 2023, reflecting a reduction of 15.6%[14]. - The total equity attributable to shareholders decreased to CNY 1,179,460,710.91 in Q3 2024 from CNY 1,237,523,025.32 in Q3 2023, a decline of 4.7%[14]. Cash Flow - The company has experienced a year-to-date cash flow from operating activities of -¥116,724,720, indicating ongoing financial challenges[2]. - Cash inflow from operating activities for the first three quarters of 2024 was 129,627,608.47 RMB, a decrease of 20.00% compared to 162,017,058.63 RMB in the same period of 2023[19]. - Cash outflow from operating activities totaled 246,352,328.67 RMB, down 22.08% from 316,385,548.28 RMB year-over-year[19]. - The net cash flow from operating activities was -116,724,720.20 RMB, an improvement from -154,368,489.65 RMB in the previous year[19]. - Cash inflow from investment activities was 256,669,258.91 RMB, significantly up from 49,857,237.97 RMB in the same period last year[19]. - The net cash flow from investment activities was 17,982,557.87 RMB, a turnaround from -186,087,700.87 RMB in 2023[19]. - Cash inflow from financing activities was 33,263,637.34 RMB, down 93.75% from 532,089,990.23 RMB in the previous year[20]. - The net cash flow from financing activities was -14,112,146.02 RMB, compared to a positive 507,601,760.70 RMB in the same period last year[20]. - The ending cash and cash equivalents balance was 197,471,311.43 RMB, down from 379,372,553.95 RMB year-over-year[20]. Market and Competition - The decline in operating revenue was attributed to a slowdown in market bidding plans and increased industry competition[6]. Product Development and Certification - In Q3 2024, the Tianji orthopedic surgical robot performed over 9,000 surgeries, bringing the total to over 27,000 surgeries since January 1, 2024, and exceeding 90,000 surgeries cumulatively[10]. - The company's orthopedic surgical navigation system and toolkits received EU CE certification, while the lumbar screw surgical planning software obtained a Class III medical device registration certificate from the National Medical Products Administration, enhancing the company's competitive edge[10]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,018[7].